Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier
Molecular Pharmaceutics · 04.11.2024 · 21 (11) · 5430-5454
DOI: 10.1021/acs.molpharmaceut.4c00604 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.09.2024. Verfasst von Courtney Culkins und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Drug Delivery Systems. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 258 Literaturangaben.
Abstract (Originalsprache)
The blood-brain barrier (BBB) is a highly selective network of various cell types that acts as a filter between the blood and the brain parenchyma. Because of this, the BBB remains a major obstacle for drug delivery to the central nervous system (CNS). In recent years, there has been a focus on developing various modifiable platforms, such as monoclonal antibodies (mAbs), nanobodies (Nbs), peptides, and nanoparticles, as both therapeutic agents and carriers for targeted drug delivery to treat brain cancers and diseases. Methods for bypassing the BBB can be invasive or noninvasive. Invasive techniques, such as transient disruption of the BBB using low pulse electrical fields and intracerebroventricular infusion, lack specificity and have numerous safety concerns. In this review, we will focus on noninvasive transport mechanisms that offer high levels of biocompatibility, personalization, specificity and are regarded as generally safer than their invasive counterparts. Modifiable platforms can be designed to noninvasively traverse the BBB through one or more of the following pathways: passive diffusion through a physio-pathologically disrupted BBB, adsorptive-mediated transcytosis, receptor-mediated transcytosis, shuttle-mediated transcytosis, and somatic gene transfer. Through understanding the noninvasive pathways, new applications, including Chimeric Antigen Receptors T-cell (CAR-T) therapy, and approaches for drug delivery across the BBB are emerging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, United States.
- Center for Cancer Engineering, Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
- Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
ORCID-Profile: Ethan Slaton, Blaise R Kimmel
Zitieren
APA
Culkins, C., Adomanis, R., Phan, N., Robinson, B., Slaton, E., Lothrop, E., Chen, Y., & Kimmel, B. R. (2024). Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier. Molecular Pharmaceutics, 21(11), 5430-5454. https://doi.org/10.1021/acs.molpharmaceut.4c00604
Vancouver
Culkins C, Adomanis R, Phan N, Robinson B, Slaton E, Lothrop E, et al. Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier. Molecular Pharmaceutics. 2024;21(11):5430-5454. doi:10.1021/acs.molpharmaceut.4c00604
BibTeX
@article{Culkins2024,
author = {Culkins, Courtney and Adomanis, Roman and Phan, Nathan and Robinson, Blaise and Slaton, Ethan and Lothrop, Elijah and Chen, Yinuo and Kimmel, Blaise R},
title = {Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {11},
pages = {5430--5454},
doi = {10.1021/acs.molpharmaceut.4c00604}
}
EUVIMED